Immunohistochemistry (IHC) was used to examine the NOXA protein levels in all available tumor tissue samples collected prior to tandem CD19/20 CAR T-cell therapy16,35 from responders who achieved a complete or partial response (n = 27) and from non-responders (n = 7). This evidence concerns the gene PMAIP1 and neoplasm.